Latest announcement: lively celebration that DIL yepin international pharmaceuticals, Bangladesh, goes online! Welcome new and old users!! Perennial recruitment of agents!
搜索
Top search terms: acatinib levatinib olaparib osimertinib venetoclax cabozantinib
News CentreMembers must read

Official wechat

Total drug product classification

Medical lett

您所在的位置：首页 > 耀品国际  > Drug database > Oncology drugs > mammary cancer

Megestrol Acetate USP

价格:￥0.00

Page hits

Recent information更多>>

产品详情

Megestrol Acetate USP

Note: before purchasing and taking medicines, a hospital genetic test report and a doctor's diagnosis report or certificate must be produced


indication
Megestrol acetate is indicated for palliative treatment of advanced breast or endometrial cancer (i.e., recurrent, inoperable, or metastatic disease). It should not be used in place of currently accepted surgery such as surgery, radiation, or chemotherapy. It is also indicated for the treatment of anorexia, cachexia or weight loss secondary to metastatic cancer.
Usage
160 mg / day (160 mg once daily).
Endometrial cancer: in divided doses of 40 to 320 mg / day (40 to 80 mg one to four times daily or one to two 160 mg tablets daily).
Continuous treatment for at least 2 months is considered an appropriate period to determine the efficacy of megestrol acetate.
Cachexia: 400 to 800 mg / day.

（此内容由www.senadadil.com提供）
上一条: FDA certificate 下一条: Olaparib

Business director official wechat

Wechat scan add

Mobile phone web


Mobile phone scanning into

Name of manufacturer：Bengal DIL DRUG nternational pharmaceutical companies

Manufacturer address：Khwaja Enayetpuri (R) Tower 17, Bir Uttam K.M. Shafiullah Road (Green Road),

Email : senadatm@yahoo.com

Dr Yap Yc ：012665  5559 

Total business responsibility of manufacturer：+86 177 7688 8407

Official wechat：YCYap17776888407

E-mail： dryapyc@yahoo.com

service time：8:30-20:30

Wechat customer service：8:30-20:30

Note: before purchasing and taking medicines, a hospital genetic test report and a doctor's diagnosis report or certificate must be produced


Copyright statement: the contents of this website are not downloaded, reproduced or mirror image created without the permission of this site and the authors themselves, and the violant (s) of this site will be held legally responsible. Text images used in this site are derived, in part, from the public network or the material site, and are in their original condition if the author (s) become aware of the warrant after such discovery that we will still timely attribution or processing in accordance with the author's own wishes, and the site shall not be liable for any event if the site is not promptly contacted.